The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical
trials as antiviral therapy, including use for infections refractory or resistant to standard …

Viruses spread rapidly and are well-adapted to changing environmental events. They can
infect the human body readily and trigger fatal diseases. A limited number of drugs are …

Artemisinin is isolated from Artemisia annua L. with peroxide-containing sesquiterpene
lactone structure. Because of its unique structural characteristics and promising anticancer …

Introduction Artesunate and other artemisinin derivatives are used in various infectious and
non-infectious diseases. We aimed to analyze available data on artesunate and artemisinin …

Human cytomegalovirus (HCMV) is a major cause of disease in immunocompromised
individuals and the most common cause of congenital infection and neurosensorial disease …

Abstract SARS (Severe Acute Respiratory Syndrome Coronavirus)-CV-2 (2019-nCov),
which showed up in China in December 2019 and spread all over the world, has becomed a …

We have recently shown that the artemisinin derivative artemisone, which was screened
against malaria in human clinical studies, is a potent inhibitor of human cytomegalovirus …

Cytomegalovirus (CMV) infections may increase morbidity and mortality in
immunocompromised patients. Until recently, standard antiviral drugs against CMV were …

Two antiviral classes, the neuraminidase inhibitors (NAIs) and polymerase inhibitors
(baloxavir marboxil and favipiravir) can be used to prevent and treat influenza infections …

The discovery of the nucleoside analogue, acyclovir, represented a milestone in the
management of infections caused by herpes simplex virus and varicella-zoster virus …